Navigation Links
Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets
Date:10/7/2010

is currently being evaluated in the BR.26 clinical trial, a Phase 3, double-blind, placebo-controlled, randomized study in patients with stage IIIB/IV NSCLC who have progressive disease following standard chemotherapy and EGFR inhibitor therapy.(3) BR.26 is led by the NCIC Clinical Trials Group (CTG).(3)

  • Crizotinib (PF-02341066)

Updated data on crizotinib (PF-02341066), a first-in-class, oral ALK inhibitor, will also be presented, from the ongoing expansion cohort from the Phase 1 study evaluating the compound in patients with ALK-positive advanced NSCLC (Abstract #366PD, October 10).(4)

  • Sunitinib

Pfizer will also present results from SUN 1087, a Phase 3 trial evaluating sunitinib plus erlotinib compared to erlotinib alone in patients with advanced NSCLC who have received at least one previous treatment with a platinum-based regimen (Abstract #LBA6, October 11).(5)  In August, Pfizer announced that this study demonstrated a statistically significant improvement in progression-free survival but not in overall survival.  Overall survival was the primary endpoint of the study and progression free survival was the secondary endpoint of the study.

Pfizer will also present progression-free survival (PFS) data as determined by blinded independent central review (BICR) from the pivotal, placebo-controlled SUN 1111 Phase 3 trial evaluating sunitinib in patients with progressive, well-differentiated pancreatic neuroendocrine tumor (NET) (Abstract #747P, October 9).(6)

  • Figitumumab

Results from a Phase 1/2 study evaluating figitumumab (CP-751,871), a selective fully human IgG2 monoclonal antibody against the IGF-1R (insulin-like growth factor 1 receptor) pathway, in patients with refractory Ewing's sarcoma and other sarcomas will be presented in a Proffe
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  iMD Companies, Inc. (ICBU) has repositioned itself as ... and grab a foothold in the hydroponic, hemp and medical ... a presence in the sector, and recently partnering with the ... hemp and medical marijuana, iMD is committing to bring its ...
(Date:1/23/2015)... LAS VEGAS , Jan. 23, 2015 Cord Blood ... CBAI ) ("CBAI" or the "Company")  filed a Preliminary Proxy ... ( www.sec.gov ) today, and provides an update for shareholders ... authorized shares is requested. Dear Shareholders, ...
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
Breaking Medicine Technology:iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
... and Tolerability, PLYMOUTH MEETING, Pa., Aug. 8 ... interim data from the first,Phase 1 clinical study ... DelConte, M.D., Vice President, Clinical Research and,Development, presented ... and Related Metabolic Disorders," during the IBC 12th,Annual ...
... Continued Investment in Clinical Development of TPI 287, BOULDER, ... announced today financial results for,the second quarter ended June 27, ... 2007 was $6.2 million, or $0.37,per share. This compares to ... million, or $0.28 per share. Included in the net loss ...
Cached Medicine Technology:Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference 2Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference 3Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference 4Tapestry Reports Second Quarter 2007 Results 2Tapestry Reports Second Quarter 2007 Results 3Tapestry Reports Second Quarter 2007 Results 4Tapestry Reports Second Quarter 2007 Results 5Tapestry Reports Second Quarter 2007 Results 6
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... January 22, 2015 Yesterday, Senator ... (D-Concord) and Kristin Olsen (R-Modesto) were honored by ... in advancing biotechnology, biomedical science, medical device and ... each received the “2014 Life Sciences Champion” award ...
(Date:1/22/2015)... Payday lending practices in four southern ... financial distress to the states that permit them, according ... Center on Race and Wealth. , While they generate ... loans at the same time substantially depress economic activity, ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Compare-autoinsurance.org has released a ... insured by an auto insurance policy . , Some ... policy. Clients should check the newly released blog post to see ... cars and dangerously damaged vehicles are some of the cars that ...
(Date:12/26/2014)... 26, 2014 The US represents the largest ... In 2013, GlobalData’s forecast estimates that sales of branded therapies ... due to the high incidence of the disease, high drug ... Japan, and China. Increased sales of CRC therapies over the ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... higher costs, study finds , FRIDAY, Sept. 18 (HealthDay ... the risk of pneumonia in certain critically ill hospital ... Wake Forest University School of Medicine in North Carolina ... breathing machines who were given stomach acid reducers to ...
... , , , ... a part of great moments throughout their career. But what about ... season fans will be able to experience the greatest of football moments ... their favorite team. , , Beginning today, legal-drinking-age consumers ...
... , IDAHO FALLS, Idaho, Sept. 18 ... conclusion of a private placement completed among numerous directors, past ... Isotopes Inc. successfully completed a private placement with certain shareholders ... In this private placement, the Company offered approximately 4 million ...
... , DURHAM, N.C., Sept. 18 Tuesday,s dedication ... Chapel Hill campus of the University of North Carolina featured ... of Cancer Care", showcasing the work of local photographers Tamara ... and Rachel were charged with photographing 55 patients, doctors, scientists, ...
... COPLEY, Ohio, Sept. 18 The Autism Family ... Keegan Family Center for Autism this afternoon, kicking off the ... , Three of the center,s partners, Robert ... Rubber Company, William Considine, president of Akron Children,s Hospital, and ...
... outlines risks of catching H1N1 from various routes , ... flu vaccines approved this week by the U.S. Food ... with compromised immune systems, according to new recommendations from ... These would include people whose immune responses are weakened ...
Cached Medicine News:Health News:Ulcer Preventative May Raise Pneumonia Risks 2Health News:Miller Lite Helps Football Fans 'Taste Greatness' by Offering Unique Experiences With Football Legends 2Health News:Miller Lite Helps Football Fans 'Taste Greatness' by Offering Unique Experiences With Football Legends 3Health News:Miller Lite Helps Football Fans 'Taste Greatness' by Offering Unique Experiences With Football Legends 4Health News:International Isotopes Inc. Announces Successful Completion of a Private Placement 2Health News:International Isotopes Inc. Announces Successful Completion of a Private Placement 3Health News:Local Photography Studio Showcased at Opening of New Hospital at University of North Carolina 2Health News:Groundbreaking Ceremony Held for New Autism Center 2Health News:Swine Flu Shots Safe for People With Weak Immune Systems: Experts 2Health News:Swine Flu Shots Safe for People With Weak Immune Systems: Experts 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: